Jeff Robinson, CEO of Wuhan, Provides Key Updates and Outlook in a New Audio Interview with SmallCapVoice.com

AUSTIN, Texas, May 22, 2020 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (SCV) and Wuhan General Group, Inc. (OTC PINK: WUHN) (the "Company" and "Wuhan"), announced today that a new audio interview with the Company is now available.

The interview featuring an overview of WUHN’s current news and moves can be heard at https://www.smallcapvoice.com/tag/wuhn/.

Jeff Robinson, CEO of Wuhan, called in to SmallCapVoice.com to go over the business model and markets that his Company operates in. Wuhan is currently positioning itself to become a major player in the estimated 146.4 billion dollars medical CBD (cannabidiol) space as well as the promising psilocybin medical health sector.

In addition to the work the Company has been doing in its core markets, Wuhan has been researching multiple medicinal mushroom types in order to formulate its upcoming range of cosmetics, coffee, and teas for commercialization in early 2020 within its M2Bio division. M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from mental illness, Alzheimer’s and Parkinson’s.

In the interview Robinson stated, “We are one of only a handful of companies in the world working psilocybin and conducting clinical trials. On the CBD side, once the lockdown, due to the pandemic, ends in South Africa, our products will be on store shelves. That would be the products in the Dr. AnnaRx and Medspresso brands. These are really exciting times for our company. We are thankful for the opportunity to share our story with our shareholders and the SmallCapVoice.com listening audience."

Dr. AnnaRx is a wholly-owned international trademark of MJ MedTech, used for the branding of its line of by-products and medical research with our high-end Broad-Spectrum Cannabidiol (CBD), is of the highest purity and potency and includes other beneficial cannabinoids, terpenes and molecules, that help promote healthy body and skin care, under the umbrella of Dr. Anna Leralta recommendations.

Wuhan General Group, Inc. is a client of StockVest. StockVest's team of top Influencers introduces publicly traded companies to a wide audience of investors from around the globe, helping public companies attain maximum market awareness resulting in increased trading volume, a broadened shareholder base and increased share valuations.

About Wuhan General Group, Inc.

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx and Medspresso brands. In addition, its new wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from mental illness, Alzheimer's and Parkinson's. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.